Headache News and Research

Latest Headache News and Research

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin.

18 Aug 2012

Mepolizumab almost halves exacerbations in severe asthma patients

The largest study of patients with severe asthma to date, published in The Lancet special issue on respiratory medicine, shows that those treated with the monoclonal antibody mepolizumab experienced an almost 50% reduction in severe exacerbations, emergency room visits, and hospitalisations compared with patients given placebo.

17 Aug 2012

Continuous oral contraceptives provide earlier relief for women with dysmenorrhea

Taking oral contraceptives continuously, rather than as traditionally prescribed for each cycle, provides earlier relief for moderate to severe menstrual cramps -- dysmenorrhea -- according to researchers at Penn State College of Medicine.

16 Aug 2012

FDA approves Intelliject's Auvi-Q for anaphylaxis

Intelliject, Inc. announced that the U.S. Food and Drug Administration approved Auvi-Q (epinephrine injection, USP) for the emergency treatment of life-threatening allergic reactions in people who are at risk or have a history of anaphylaxis. This is the first-and-only compact auto-injector with audio and visual cues that guide patients and caregivers step-by-step through the injection process.

13 Aug 2012

Positive results from Acorda post-marketing commitment study of dalfampridine-ER for MS

Acorda Therapeutics, Inc. today announced top line results from a post-marketing commitment study evaluating a 5mg dose of dalfampridine-ER to improve walking in people with multiple sclerosis. The study failed to confirm efficacy of the 5mg dose.

13 Aug 2012

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Genentech, a member of the Roche Group, today announced that Lucentis (ranibizumab injection) was approved by the U.S. Food & Drug Administration (FDA) for treatment of diabetic macular edema (DME), an eye condition in people with diabetes that causes blurred vision, severe vision loss and sometimes blindness

12 Aug 2012

Alfa Wassermann, Salix enter license agreement for EIR formulation of rifaximin

Salix Pharmaceuticals, Ltd. and Alfa Wassermann S.p.A. today announced that they have entered into an exclusive agreement by which Salix has licensed rights in the United States and Canada to an extended intestinal release (EIR) formulation of rifaximin for gastrointestinal and respiratory indications, including Crohn's disease.

9 Aug 2012

Risk of arteriovenous malformation bleeding is eight times higher during pregnancy

A new study supports what neurosurgeons have long suspected—that pregnancy is an important risk factor for bleeding from arteriovenous malformations (AVMs) in the brain, reports the August issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

8 Aug 2012

Orexigen Therapeutics reports net loss of $16.7 million for second quarter 2012

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the second quarter of 2012.

7 Aug 2012

Early CT ‘definitive’ for subarachnoid hemorrhage diagnosis

Cerebrospinal fluid analysis is only necessary for patients with thunderclap headache and a negative computed tomography scan if they undergo imaging more than 6 hours after headache onset, research suggests.

6 Aug 2012

First generic versions of Singulair receive FDA approval for treatment of asthma, allergies

The U.S. Food and Drug Administration today approved the first generic versions of Singulair (montelukast sodium) for use in adults and children to control asthma symptoms and to help relieve symptoms of indoor and outdoor allergies.

6 Aug 2012

Sanofi-aventis receives FDA approval for Zaltrap to treat colorectal cancer

The U.S. Food and Drug Administration today approved Zaltrap (ziv-aflibercept) for use in combination with a FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy regimen to treat adults with colorectal cancer.

6 Aug 2012

Novel integrase inhibitor dolutegravir shows promise for HIV-1 treatment

The once-daily integrase inhibitor dolutegravir has shown promise in a phase III noninferiority study comparing it with twice-daily raltegravir for treatment of HIV-1, indicate study results presented at the 19th International AIDS Conference in Washington DC, USA.

3 Aug 2012

GSK begins shipping the first lots of 2012-2013 seasonal influenza vaccines

GlaxoSmithKline announced today it has begun shipping the first lots of 2012-2013 FluLaval (Influenza virus vaccine) and Fluarix (Influenza Virus Vaccine) to CDC distribution centers and U.S. healthcare providers.

1 Aug 2012

Health Union releases results of 'Migraine In America 2012' study

Health Union, LLC, released the results of its landmark study "Migraine In America 2012" tonight via a live web conference.

31 Jul 2012

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

Array BioPharma today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in 157 osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).

31 Jul 2012

Early CT ‘definitive’ for subarachnoid hemorrhage diagnosis

30 Jul 2012

Sunovion launches ZETONNA Nasal Aerosol for allergic rhinitis

Sunovion Pharmaceuticals Inc. today announced the nationwide availability of ZETONNA (ciclesonide) Nasal Aerosol, 74 mcg once-daily, for the treatment of allergic rhinitis (AR), also known as hay fever or nasal allergies. ZETONNA is a corticosteroid indicated for the treatment of symptoms associated with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and adolescents 12 years of age and older.

30 Jul 2012

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

Genentech, a member of the Roche Group, today announced that the BREVACTA study of ACTEMRA (tocilizumab) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its primary endpoint.

28 Jul 2012

Takeda resubmits alogliptin and fixed-dose combination therapy NDAs with FDA

Furiex Pharmaceuticals, Inc. today confirmed that Takeda Pharmaceutical Company Limited announced that its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. has resubmitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for alogliptin and fixed-dose combination therapy alogliptin and pioglitazone for the treatment of type 2 diabetes in adults.

28 Jul 2012

Headache News and Research

Latest Headache News and Research

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Mepolizumab almost halves exacerbations in severe asthma patients

Continuous oral contraceptives provide earlier relief for women with dysmenorrhea

FDA approves Intelliject's Auvi-Q for anaphylaxis

Positive results from Acorda post-marketing commitment study of dalfampridine-ER for MS

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Alfa Wassermann, Salix enter license agreement for EIR formulation of rifaximin

Risk of arteriovenous malformation bleeding is eight times higher during pregnancy

Orexigen Therapeutics reports net loss of $16.7 million for second quarter 2012

Early CT ‘definitive’ for subarachnoid hemorrhage diagnosis

First generic versions of Singulair receive FDA approval for treatment of asthma, allergies

Sanofi-aventis receives FDA approval for Zaltrap to treat colorectal cancer

Novel integrase inhibitor dolutegravir shows promise for HIV-1 treatment

GSK begins shipping the first lots of 2012-2013 seasonal influenza vaccines

Health Union releases results of 'Migraine In America 2012' study

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

Early CT ‘definitive’ for subarachnoid hemorrhage diagnosis

Sunovion launches ZETONNA Nasal Aerosol for allergic rhinitis

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

Takeda resubmits alogliptin and fixed-dose combination therapy NDAs with FDA

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Headache News and Research

Latest Headache News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in